Avalo Therapeutics (AVTX) Shares Outstanding (2014 - 2026)
Avalo Therapeutics (AVTX) posted Shares Outstanding (Entity) of $58534.0 for Q2 2023, up 6.34% on a QoQ basis from $55046.0 in Q1 2023, and up 9940.14% year-over-year from N/an in Q2 2022.
Avalo Therapeutics (AVTX) Shares Outstanding (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $58534.0 for Q2 2023.
- Quarterly Shares Outstanding (Entity) rose 9940.14% year-over-year to $58534.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $58534.0 (up 9940.14% YoY) and the FY2022 annual result came in at $39325.0, up 6645.28% from the prior year.
- Shares Outstanding (Entity) was $58534.0 for Q2 2023 at Avalo Therapeutics, up from $55046.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $58534.0 in Q2 2023 and bottomed at $1.0 in Q3 2022.
- A 5-year average of $23185.2 and a median of $23361.5 in 2020 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) tumbled 100.0% — and 2023, when it jumped 9940.14%.
- Avalo Therapeutics' Shares Outstanding (Entity) stood at $15423.0 in 2019, then soared by 68.99% to $26063.0 in 2020, then tumbled by 97.76% to $583.0 in 2021, then surged by 6645.28% to $39325.0 in 2022, then jumped by 48.85% to $58534.0 in 2023.
- Business Quant data shows AVTX's Shares Outstanding (Entity) at $58534.0 in Q2 2023, $55046.0 in Q1 2023, and $39325.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 47.82 Bn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.44 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 11.23 Bn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 62.19 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 198.10 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 20.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.11 Mn |
| Dec 31, 2025 | 13.40 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 10.83 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 5.55 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 859,381.00 |
| Dec 31, 2023 | 277,727.00 |
| Sep 30, 2023 | 195,006.00 |
| Jun 30, 2023 | 58,263.00 |
| Mar 31, 2023 | 48,884.00 |
| Dec 31, 2022 | 39,233.00 |
| Sep 30, 2022 | 1.00 |
| Jun 30, 2022 | 583.00 |
| Mar 31, 2022 | 583.00 |
| Dec 31, 2021 | 583.00 |
| Sep 30, 2021 | 12,083.00 |
| Jun 30, 2021 | 12,083.00 |